RecruitingPhase 2NCT06914674
Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas
Studying Pancreatic solid pseudopapillary neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fudan University
- Principal Investigator
- Guopei Luo Prof, MDShanghai Cancer Center
- Intervention
- Tamoxifen 20 mg(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 14-80 years · All sexes
- Timeline
- 2025 – 2028
Study locations (1)
- Shanghai Cancer Center, Shanghai, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06914674 on ClinicalTrials.govOther trials for Pancreatic solid pseudopapillary neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07183280Multicentric Database for Solid Pseudopapillary Neoplasm of the PancreasFudan University
- RECRUITINGNCT05604716Cross-sectional Follow-up on Digestive and Social Functions of SPNPeking Union Medical College Hospital
See all trials for Pancreatic solid pseudopapillary neoplasm →